Digital patient support programs are widely deployed, yet only about 40% of eligible patients actively use them—leaving significant value unrealized. Based on global research with 75 senior biopharmaceutical leaders, this article explores why digital adoption has not translated into patient impact and what leading organizations are doing differently. The findings reveal that success depends less on technology alone and more on early activation, integration into care pathways, disciplined measurement beyond adherence, and the ability to turn program data into decision‑ready evidence.

The most effective models combine digital scale with human support, balance global platforms with local execution, and treat patient support data as a strategic asset. This article outlines five insights leaders can use to strengthen digital patient support and drive measurable outcomes.

What you’ll learn

• Why near‑universal adoption of digital patient support has not translated into sustained patient engagement or measurable impact
• How leading organizations are re‑designing activation, measurement, and governance to improve uptake and scale performance across markets
• What differentiates digital patient support models that generate decision‑ready insight and evidence from those that deliver services alone